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 The drug discovery process is an extremely long and expensive process that 
modern computational methods help to alleviate. Through the use of computational 
methods, we provide information and insight into the activation methods of class B 
GPCRs so that future drugs can be developed to have less side effects. The first study 
focuses on the corticotropin releasing factor receptor, which is a good drug target for 
anxiety and depression. A mechanism of activation was theorized which focuses less on 
molecular switches (as has been the focus of several papers) and more on large scale 
conformation at the intracellular region of the receptor and the C-terminal helix. We also 
developed a homology model for the complete receptor, which previously did not exist. 
The second study focused on the glucagon-like-peptide receptor which is a good drug 
target for treating type 2 diabetes. Here we explored the difference between full agonist 
activation and biased agonist activation. A distinctive conformational change of the C-
terminal helix in the biased system was linked to allowing G protein docking, while 
blocking arrestin proteins from docking. Our findings elucidate details on GPCR 
activation which can be used to develop more efficient drugs on these receptors and 
provides insight into developing more specific drugs on other class B GPCRs.   
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Introduction to Computational Drug Design 
1.1 The Need for a Computational Approach 
Drug development from preclinical research to FDA approval is a long and 
expensive process, spanning an average of 12 years and over a billion dollars. A large 
portion of this time is spent in the lab where tens of thousands of drug compounds are 
created and screened. The California Biomedical Research Association discussed this 
timeline and claims only about 5 in 5,000 drugs will enter clinical trials (human 
testing). If you’re lucky, then one of these compounds will be approved by the FDA1. 
 Creating and screening compounds is the most time consuming portion of drug 
discovery1 and can be very expensive. Since the drug discovery process is so labor 
intensive, computational tools are developed to accelerate the time frame and reduce 
cost significantly. These tools can quickly predict the binding behavior of a specific 
target with a library of compounds. Computer-aided drug design (CADD) can follow 
either structure-based drug design (SBDD) or ligand-based drug design (LBDD). In 
SBDD, the binding site is identified and used to evaluate ligands and predict their 
protein-ligand interactions. Ligands can be docked and scored in a virtual screen. In 
LBDD, the target protein is unavailable and information is taken from a number of 
ligands. A relevant receptor target can be used to evaluate properties associated with 
biological activation. Quantitative structure-activity relationships (QSAR) and 
pharmacophore modeling can be utilized in a virtual screen2.  
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 Tools like Maestro and Visual Molecular Dynamics (VMD) can be used to 
analyze and build high resolution structures to make visualization easier. These tools 
can be used to refine the crystal structure of proteins and ligands. Refinement consists 
of a various optimizations including the addition of hydrogen atoms, optimization of 
hydrogen bonds, assigning proper bond orders, and fixing atomic clashes3. High 
throughput screening (HTS) can then be used to quickly filter through ligands to 
determine their binding affinity. Binding energy calculations further narrow down the 
number of ligands that become lead compounds in the drug development process.  
 Overall, computational methods are greatly beneficial to the field in two main 
ways: to more quickly and cheaply determine suitable drug candidates, and to allow 
for greater visualization of how the ligands interact with the target receptor. This 
thesis utilizes computational methods to better understand the activation mechanisms 
of class B G-protein-coupled receptors (GPCRs) bound to peptide ligands. Two 
studies are performed: the first on the corticotropin-releasing-factor 1 receptor 
(CRF1R) bound to the peptide agonist urocortin, and the second on the glucagon-like-
peptide 1 receptor (GLP1R) bound to both a full agonist and a biased agonist. The 
findings of these two studies will aid in the development of more specific drugs 
targeting these receptors.  
1.2 Methodologies 
1.2.1 Bioinformatics. Bioinformatics can be defined as the conceptualization of 
biological data using informatics techniques such as computer science, mathematics, and 
statistics. The predominant analyses that bioinformatics focuses on deals with large 
datasets associated with the structures of macromolecules, full genomic sequences, and 
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genomic experimental results. Bioinformatics can also be useful in the drug design 
process through sequence alignment techniques, homology modeling methods, and large-
scale analyses4.  
1.2.2 Homology modeling. High resolution structures are critical in rational drug 
design to provide more meaningful results and conclusions. However, there are not 
always high resolution structures available for a given receptor. When this is the case, 
homology modeling can be utilized to create a structure based on homologs of the 
receptor. I-TASSER is one such tool that is used for homology modeling and works by 
creating a structure from its FASTA file sequence based on templates from the Protein 
Data Bank5 (PDB). PDB is an online database composed of 3D structures of proteins 
which have been obtained from either NMR or X-ray crystallography experiments. I-
TASSER works by comparing an inputted sequence with the sequences found in PDB to 
generate possible structures. Based on the sequence and the templates from PDB, 
theoretical models can be built with a higher degree of certainty due to structural 
similarity of these proteins from an evolutionary standpoint6. Maestro also has a useful 
tool for homology modeling called the Protein Preparation Wizard. This tool checks for 
inconsistencies in the structure and has the power to edit physiochemical properties such 
as charge and hydrogen bonding as well as optimize the overall geometry of the complex.  
1.2.3 Molecular docking. Molecular docking software is used to determine if a 
compound can bind to a specific target. There are a number of areas where this technique 
can be utilized. Virtual screens can utilize molecular docking software to help identify 
lead compounds which is a much faster process then wet lab testing7. Molecular docking 
software can generate the molecular surface for the receptor based on high resolution 
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structures from the homology model. The binding site is then marked with potential 
binding locations represented by spheres. The best scored orientation is outputted as the 
binding pose9-10. There are several types of scoring functions that can be used. One 
example is a force-field based approach which derives physical-based functional forms 
from experimental data to estimate binding affinity. Another approach is empirical 
scoring which simplifies the parameters of force-field based approaches to determine 
approximately which interactions are more favorable. This technique is consequently less 
accurate, but substantially faster. A 3rd approach is knowledge-based scoring functions 
which is based on binding interactions that are known to be more frequent then expected 
by random distribution. This method has been shown to be faster than force-field based 
approaches and less prone to over-fitting complications that are associated with empirical 
approaches11. Maestro’s Glide docking tool was used to dock the ligands in this study. 
Extra precision (XP) was used to dock the small molecule ligands and standard precision-
peptide (SP-peptide) was used to dock the peptide ligands.  
1.2.4 Molecular dynamics simulations. Molecular dynamics simulations, first 
developed in the 19070s12, mimic the way molecules move and behave in a three-
dimensional model which can give a deeper understanding of the binding interactions 
between ligand and receptor. Some common molecular dynamics force-fields include 
AMBER13 and NAMD14 which only differ by the approach they take in setting up 
parameters.  Properties considered during simulations include atomic diameters, bonds 
connecting atoms, bond angles, and electric charges. Environmental factors are also 
considered such as pH, temperature, and pressure. Force vectors are calculated to define 
the direction and distance of the movement of the molecules in the simulation15. 
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Molecular dynamics simulations are run until an equilibrium is reached. A series of 
snapshots can be produced to create a trajectory of the system as it moves throughout the 
simulation to make analysis easier. Once complete, this opens up the doors to further 
analysis on the complex to better understand the binding energies and interactions of the 
system.  
1.2.5 MMGBSA binding energy calculations. Molecular mechanics generalized 
Born surface area (MMGBSA16) can be used to calculate binding energies for a given 
system. The binding free energy is calculated using the following equation: ΔGbind = Gc – 
(Gp + GL). GC represents the protein-ligand complex’s free energy, Gp is the free energy 
of the protein, and GL is the free energy of the ligand. These binding energies can provide 
important details about how a given ligand interacts with its receptor which can be used 
to better understand its activation mechanism. MMGBSA analysis considers three main 
components: electrostatic, van der Waals, and surface area17. This analysis is performed 
on ligand only, receptor only, and receptor-ligand complexes to determine total binding 
energy. The results allow us to determine how stable a given ligand can bind to a given 
receptor. This technique has uses in the drug development process to help screen for 
compounds that have the highest binding stability.  
1.3 Thesis Outline 
In chapter 2, the binding of a peptide agonist and a small molecule antagonist to the 
corticotropin-releasing factor receptor type 1 (CRF1R) is analyzed. The CRF receptor is a 
Class B G protein-coupled receptor (GPCR) that is activated by a peptide hormone (CRF) 
for stress responses. Although CRF1R is a good drug target for treating depression, 
inflammation, and anxiety, there is no FDA approved drug. There is also no high 
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resolution structure of CRF1R in complex with the peptide hormone and its activation 
mechanism remains elusive. In this study, we explore conformational changes of CRF1R 
in complex with a peptide agonist (Urocortin) and small molecule antagonist (CP 
376395). The structure model of CRF1R was constructed using I-TASSER which 
generated several models based on the top ten PDB hits. The model selected prioritized 
PDB 4K5Y because it represented inactivated CRF1R. Urocortin (PDB 2RMG) and CP 
376395 were docked to the receptor.  The docked systems were subjected to a total of 4 
µS (2 x 2 µS) molecular dynamics simulations, followed by trajectory clustering and 
simulation interaction diagram analysis. We examined three molecular switches (Ionic 
lock, Polar lock, and Rotamer Toggle switch) that were thought to play key roles in the 
activation of the receptor and show different conformations between peptide and small 
molecule systems. The extracellular loop 3 (EL3) and helix 8 also showed high flexibility 
between agonist and antagonist conformations. Finally, we compared our receptor 
conformations to existing GPCRs docked to the G-Protein to predict activation. Our 
findings point toward a new mechanism of activation favoring large scale conformational 
changes of the C-terminal helix and transmembrane helices as opposed to molecular 
switches which have been the focus of several previous studies. Our findings also provide 
insights for developing this class of drugs on CRF1R. 
In chapter 3, the activation mechanism of a biased agonist is analyzed in the 
glucagon-like-peptide-1 receptor (GLP1R). The GLP1 receptor is a class B G protein-
coupled-receptor (GPCR) which controls insulin secretion. For this reason, it is a good 
drug target for type 2 diabetes (the condition in which the body cannot produce enough 
insulin). Agonist drugs can be used to stimulate insulin secretion, but are typically not 
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specific to the G protein pathway which can lead to side effects. Biased agonists are 
specific to one particular pathway, but their activation mechanism is poorly understood. 
In this study, we aim to develop a better understanding of biased activation so that future 
drugs can be designed to be more specific and have less side effects. We propose that key 
conformational changes in the C-terminal helix of the biased system allow for binding of 
the G protein, but block binding of arrestin proteins. The structure of the GLP1 receptor 
was obtained from the Protein Data Bank (PDB 6b3j). The full agonist was obtained from 
PDB 5nx2 and the biased agonist was obtained from PDB 6b3j. A full agonist, biased 
agonist and APO form system was prepared and run under MD simulations for 2µs each. 
Trajectory clustering analysis, simulation interaction diagram analysis, and MMGBSA 
analysis was performed. Comparisons were made to G protein docked and arrestin 
docked structures obtained from PDB to determine activation. It was concluded that the 
C-terminal helical conformation of the biased system was responsible to the specificity 
toward the G protein pathway. Our results provide insight into developing a new, more 





Binding of Peptide Agonist Urocortin and Small Molecule Antagonist CP 376395 to 
the CRF1 Receptor Probed by Molecular Dynamics Simulations 
2.1 Introduction  
 2.1.1 G protein-coupled-receptors. G protein-coupled-receptors (GPCRs) are 
known for being the largest family of cell surface receptors. They share a structural 
similarity with each other in that they all have seven transmembrane helices connected by 
alternating intracellular and extracellular loops, an extracellular N-terminus, and an 
intracellular C-terminus. In order for a GPCR to enter a state of activation, it must 
undergo a molecular switch. A molecular switch can be defined as non-covalent 
intramolecular interactions that have to be disturbed in order for activation to occur18. 
GPCRs can be broken up into five distinct classes: Class A (rhodopsin), Class B 
(secretin), Class C (glutamate), Class D (adhesion), and Class E (frizzled)19. They are 
important drug targets due to the way they initiate signaling cascades which spread 
throughout the body. Class A GPCRs are the largest and most understood class of GPCR 
(containing over 700 receptors). Class B GBCRs are less understood, which is why they 
were chosen as the focus for this paper. Class B GPCRs are distinguished by their two 
domains: a large extracellular domain (ECD) which plays an important role in activation, 
and a helical seven transmembrane domain (TMD). Altogether, there are 15 known 
receptors in the Class B family that are important drug targets for diabetes, osteoporosis, 
hypercalcemia and more. Unlike Class A receptors, there is little known about the 
activation mechanism of Class B GPCRs beyond a general binding mechanism for 
peptide hormones20. When binding, the C-terminal end of the peptide attaches to the 
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extracellular domain initiating a conformational change that allows the N-terminal end of 
the peptide to bind inside the seven transmembrane pocket. This conformational change 
allows for interaction with the G protein19.  
2.1.2 The cortictropin-releasing-factor receptor. The corticotropin-releasing 
factor receptor type 1 (CRF1R) is a Class B GPCR that controls how the body responds 
to stress and is predominantly found in the central nervous system21. For this reason, 
CRF1R is a good drug target for things such as anxiety, depression, inflammation, and 
other stress related issues22. While the activation mechanism remains largely unknown, 
Seidal20 proposes that agonists adopt different folds than antagonists to stabilize the 
transmembrane domain. The agonists produce a wider pose than antagonists, which 
affects the activation of the receptor. These differences occur at helices VI and VII and 
involve a bending around the glycine hinges. Seidal termed these two distinct poses as 
‘wide’ (for agonists) and ‘compact’ (for antagonists). Seidal also confirmed that both 









Figure 2. Snake diagram of human CRF1R taken from GPCRdb23-24. Generic numbering of this 
receptor can be found in Appendix A, table 5.  
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2.1.3 Molecular switches. We also examined three molecular switches and a 
conserved sequence motif found in CRF1R. First, the Ionic lock which is an interaction 
located between Arg151 on TM3 and Glu209 on TM3. The Polar lock is also located 
between TM2 and TM3, but is an interaction that occurs between His155 and Glu209 
(see appendix A, table 5 for generic numbering). The Rotamer Toggle switch is located 
between TM5 and TM6 at residues Tyr327, Leu323, and Phe284. GWGxP is a conserved 
sequence motif found among all class B GPCRs that we examine for structure/rotational 
differences between agonist and antagonist bound systems. Xu25 examined 
conformational differences at these locations between different small molecule 
antagonists and apo-form CRF1R. Xu concluded that the ionic lock is broken during 
antagonist binding, but remains formed in the apo form. Xu found that the Polar lock was 
unaffected by the binding of antagonists. Xu noted a distinct rotational difference of the 
Rotamer Toggle switch between apo-CRF1R and antagonist-bound CRF1R. Finally, Xu 
noted that the GWGxP motif plays no role in the inactivation of CRF1R. In this paper, we 
aim to examine these locations on a peptide agonist and small molecule antagonist 
system for conformational differences.  
2.1.4 Experimental overview. In this study, we explore how these 
conformational changes affect the activation of CRF1R with a peptide agonist 
(Urocortin) and small molecule antagonist (CP 376395). We aim to expand the 
knowledge on class B GPCR activation mechanisms through examining the binding 
poses with the above mentioned ligands under molecular dynamics simulations. The PDB 
database does not have the complete structure of CRF1R, but does have its 
transmembrane domain and extracellular domain individually. The full structure 
12 
 
(obtained from I-TASSER) was compared to crystal structures from PDB IDs 4K5Y and 
3EHU respectively so that the ligands could be docked. The peptide ligand was also 
obtained from PDB (2RMG). The small molecule antagonist CP 376395 was obtained 
from the 4K5Y system. Ligands were docked in Maestro and molecular dynamics 
simulation, Trajectory Clustering Analysis, and Simulation Interaction Diagram (SID) 
analyses were performed for both systems. Our systems were compared to other class B 
GPCRs bound to the G protein for comparison.  
 
2.2 Methods  
2.2.1 Generating the homology model: The sequence for CRF1R was download 
and I-TASSER26 was used create several models based on the top ten PDB hits. The 
model selected prioritized PDB 4K5Y because it represented the transmembrane domain 
of inactivated CRF1R. This model was then opened in Maestro for further preparation.  
2.2.2 Protein and ligand preparation: Maestro’s Protein Preparation Wizard27 
was used to prepare the CRF1R model for docking and simulations. Preprocessing was 
performed on the protein which corrected the bond orders, added hydrogens and disulfide 
bonds where necessary, and removed water where appropriate. The model then had its 
charge state optimized followed by a restrained minimization. A 3D structure for the 
peptide agonist (Urocortin) was obtained from the protein data bank (PDB ID 2RMG). 
The crystal structure of the small molecule antagonist (CP 376395) was obtained from 
the transmembrane structure (PDB ID 4K5Y). The same preprocessing, optimization, and 
minimization as before was performed on these ligands. 
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2.2.3 Docking: The docking of the peptide ligands to the receptor was done in 
Maestro using Glide Docking. First the receptor grid was generated, then the ligands and 
receptors were specified. Default settings were used under the SP-Peptide mode to dock 
the prepared peptide ligand using an OPLS3 force field28-30. The docked complex was 
then loaded into VMD to optimize the binding pose. The C-terminal end of the peptide 
ligand was oriented to bind to the ECD in correspondence with Grace et al.31-32 who 
suggested that, due to the hydrophobic nature of the region, the C-terminal end expresses 
receptor specific binding to the ECD. The small molecule ligand was already in complex 
with the receptor in the 4K5Y structure.  
2.2.4 Molecular dynamics simulation: The receptor-ligand complexes from the 
docking step were used to construct molecular dynamic simulation systems. The 
complexes were aligned in a membrane set to the helices of the transmembrane domain. 
The complexes were then solvated using a water box with a predefined SPC water model. 
To help neutralize the system, 0.15M NaCl was added to the system. An OPLS3 force 
field was used to build these systems using the Desmond System Builder in Maestro. The 
complexes ran for a total of 4 µS under these conditions.  
2.2.5 Trajectory clustering analysis: The Desmond33 trajectory tool in maestro 
was used to group the structures that were produced during the final 100 ns of the 
simulation. Backbone RMSD was selected as a structural similarity metric and 
hierarchical clustering was selected with average linkage. The merging distance cutoff 
was set to 2.5 Å. Frequency was set to 2 with the number of frames set to 250 and 
number of threads set to 2. This calculation was performed for both agonist and 
antagonist structures. Structures of the most abundant cluster (those with a frequency of 
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2% or greater) were saved for further analysis. The most abundant structure for each 
complex was than aligned and superimposed to compare conformation differences. The 
three regions to compare were the extracellular domain, the transmembrane bundle, and 
helices 8. 
2.2.6 Simulation interaction diagram (SID) analysis: The SID tool can be 
found in maestro under the tasks menu and was used to analyze the interactions between 
the protein and ligand. Calculations performed include: Root Mean Square Deviation 
(RMSD), Root Mean Square Fluctuation (RMSF), secondary structure changes, and 
protein-ligand contacts. The RMSD calculation measures the displacement change of 
atoms for the entire trajectory with respect to the reference frame. The RMSD equation 
used for this calculation is as follows: 
 33 
Where N is the number of atoms, t is time, and r is the position of the atom. RMSF 
analyzes changes along a protein chain or molecule. The RMSF equation used for this 
calculation is as follows: 
33 
Where T is the trajectory, t is time, r is residue position and the < and > signs indicate 
that the average of the square distance is taken. The secondary structure changes are 
monitored for the entirety of the simulation. Structures recorded include alpha-helices 
and beta strands. The simulation also records how many protein-ligand contacts exist and 
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of what kind (such as hydrophobic, H-bond, etc.). For the peptide complex, a protein only 
analysis was performed since the program could not discern the difference between the 
protein receptor and the peptide ligand. Its protein contacts were determined using 
Protein Interaction Analysis under the biologics tasks menu. The resulting data was used 
to make a table of interactions which was used to make a contact map in VMD. 
2.2.7 Simulation event analysis: The SID analysis calculated total RMSD for the 
entire complex. To calculate select regions (i.e. the extra cellular domain, transmembrane 
domain, and helices 8) the systems were aligned in maestro with their respective starting 
positions based solely on their transmembrane domain. Maestro’s simulation event 
analysis tool was then used to calculate RMSD of each region separately for the entire 
trajectory. Radius of gyration was also used on select regions. 
2.2.8 Comparison to other GPCRs: Five different PDB entries (3sn634, 5g5335, 
5vai36, 5uz737, 6b3j38) were aligned based on their transmembrane domain and then 
superimposed on our agonist and antagonist systems to look for key conformational 
differences associated with G protein docking. The key region associated with the ability 
for the G-protein to dock to the receptor is the C-terminal helix 8. Figures were generated 
comparing the C-terminal region of all five PDB entries with our agonist and antagonist 
systems.  
2.2.9 Matlab scripting: Scripts were developed in Matlab for the purpose of 
generating graphs for RMSD data, Radius of Gyration, and molecular switches. The 
RMSD script took the RMSD of the ligand, transmembrane, N-terminal, and C-terminal 
domains obtained from the simulation event analysis data and plotted them all together to 
compare these regions between the agonist and antagonist systems. The radius of 
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gyration script generated two histograms comparing the N-terminal regions in one graph, 
and the C-terminal region in the other. The script for the molecular switches was 
developed to analyze all clusters in the simulation, not just the most abundant. The script 
worked by loading in the trajectories of both complexes, averaging the values to smooth 
out the data, and creating a graph of distance (Å) versus time (ns) in the case of figures 
13 and 15 or torsion angle (degrees) versus time (ns) in the case of figures 17-19. These 
graphs aided in showing the conformation of key residues over the entire simulation. 
 
2.3 Results 
2.3.1 I-TASSER generated a homology model for CRF1R. Crystal structures 
exist for the transmembrane and extracellular region individually, but not together (PDB 
ID 3EHU and 4K5Y). Figure 3 compares both crystal structures with the TASSER 
model. The small molecule ligand is already docked in the crystal structure and aided in 
justifying our docking position of the ligand into our model. Docking orientation of the 















Figure 3. Comparison between our homology model and the crystal structures (PDB 








































Figure 4. Docked peptide agonist urocortin and small molecule antagonist CP 376395 to 
the I-TASSER generated model. 
 
2.3.2 The antagonist model and the agonist model produced different poses. 
Seidel20 proposed distinct conformational differences of helixes 6 and 7 between agonist 
and antagonist systems. Agonist should produce a “wide” receptor pose and antagonists 













































































































































































































































































































































































































































































































































































































































































































































































reveals that indeed the antagonist model produces the aforementioned compact pose and 
the agonist model produces the wide pose. We compared our docking position to Jazayeri 
et. al.39 who docked a peptide ligand into another GPCR, GLP1 (Figure S3 and S4). 
2.3.3 Flexibility was observed in the TMD, ECD, and helices 8. In the 
transmembrane domain, two distinct groups are seen. In one group, TMs 2, 3 and 4 retain 
their position in both systems and develop kinks in the agonist. The other group contain 
helices 1 and 5-7. In this group, the kinking is similar in both systems, but the helices are 
significantly shifted in the small molecule. Most helices showed a large conformational 
shift (Figure 7). The RMSD data from this region showed a great deal of difference 
between agonist and antagonist systems (Figure 5). The extracellular domain also 
showed a great deal of flexibility. The agonist conformation showed the extracellular 
domain adopt an open conformation by folding to the right, whereas the antagonist 
conformation adopted a more vertical conformation (Figure 6).  The RMSD data shows 
more flexibility in the agonist system then the antagonist (Figure 5). Helices 8 showed a 
different conformation for each systems: the peptide agonist tilted upward, the small 





Figure 5. Root Mean Square Deviation (RMSD). Used to measure the average change in 
displacement of a selection of atoms for a particular frame with respect to a reference 


















































Figure 6. Peptide agonist and small molecule antagonist most abundant conformation for 
full system, 7TM domain, extracellular domain, and the C-terminal Helix 8 after 2000ns. 






Figure 7. Pairwise helical comparison of the transmembrane region. Images taken from 
the most abundant conformations between agonist and antagonist systems. Blue = peptide 
agonist, red = small molecule antagonist.  
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2.3.4 Different types of protein-ligand interactions were observed. The peptide 
agonist ligand experienced primarily hydrogen bonding and van der Waals interactions. 
Salt bridges were formed at residues 153D and 365E (Figure 8). The small molecule 
antagonist experienced a mixture of hydrophobic, hydrogen bonding, and polar 
















13 L 31 A VDW 
118 V 30 Q HB 
120 V 30 Q HB, VDW 





156 D 4 I HB 
157 G 6 L VDW 
194 R 9 D HB 
224 Y 8 L HB 
231 N 9 D VDW 
365 E 21 Q HB, Salt 
366 D 25 R HB 
374 I 18 L VDW 
  
Residue number and 1-letter amino acid code for both receptor and ligand with their 





Figure 8. Ligand-protein interactions for peptide agonist system. For the residue contacts, 
bottom numbers represent residues on the receptor. Top numbers represent residues on 






Figure 9. Ligand-protein interaction for small molecule antagonist. The blue molecules 
indicate polar interaction and the green molecules indicate hydrophobic interactions. On 
the histogram, the purple bars indicate hydrophobic interactions and the green bar 






















Protein Ligand Contacts for CRF1R and a 
Peptide Agonist




2.3.5 Different structural elements and RMSF values were observed. The 
small molecule system displays significantly more beta sheets than the peptide system. 
Differences also arise amongst the alpha helices between both systems (Figure 10). 
Notable differences include: significantly more beta sheets in the extracellular domain of 
the antagonist, different levels of helical structure and kinks in the transmembrane 
helices, and significantly less helical structure in the C-terminal region of the antagonist 
system. Our protein RMSF data shows that the receptor undergoes slightly different 
dynamic responses for both of the ligands tested. The protein Cα Root Mean Square 
Fluctuation (RMSF) values for the peptide agonist and small molecule antagonist 
complexes are depicted in Figure 11. The mean values for each region can be found in 
Table 1. The C and N terminal regions proved, as expected, to be regions of high 
flexibility and as such exhibited high RMSF values. The TM region proved to be of 
similar flexibility to the loops, having RMSF values very close together. This is 
consistent with Seidel’s3 findings in that the data supports both agonist and antagonist 
models maintain integrity and flexibility during simulation. Also consistent with Seidel’s3 
findings is Extracellular loop 3’s (E3) RMSF value. E3 showed a much higher RMSF 
value than any of the other loops, indicating high levels of flexibility. Seidel proposed 
that the receptor takes on a wide pose (in agonists) and a compact pose (in antagonists) 




















I1 3.17 3.27 
TM2 2.99 2.39 
E1 2.17 1.51 
TM3 2.44 2.72 
I2 1.96 1.74 
TM4 1.91 1.80 
E2 2.25 2.27 
TM5 2.70 2.49 
I3 1.99 2.36 
TM6 2.51 2.31 
E3 4.75 3.90 
TM7 2.74 2.36 
C-terminal 5.53 4.45 
All I’s 2.37 2.46 
All E’s 3.06 2.57 
All Loops 2.72 2.51 
All TM’s 2.68 2.57 






Figure 10. Secondary structure elements (SSE) for agonist and antagonist. Orange 
represents alpha helices. Blue represents beta sheets. N-terminal region: 0-145, TM1: 
146-170, TM2: 178-205, TM3: 215-248, TM4: 255-281, TM5: 298-330, TM6: 339-362, 
TM7: 370-395, C-terminal region: 396-444. Key regions of difference are indicated by 










Figure 11. Cα RMSF diagram of small molecule and peptide agonist. Data taken after 
2000ns to measure flexibility at each region. N-terminal region: 1-102, C-terminal 
region: 393-444. Helices: H1: 103-144, H2: 149-175, H3: 185-219, H4: 226-254, H5: 
268-298, H6: 304-332, H7: 339-392. Intracellular loops: I1: 145-148, I2: 220-225, I3: 




Figure 12. Ligand RMSF for small molecule antagonist to measure flexibility of each 





































































































Protein RMSF Between Peptide Agonist and SM Antagonist
SM CA Pep_Ago CA












2.3.6 The radius gyration data showed shift in the agonist system. Both the N-
terminal region (extracellular domain) and the C-terminal region (helix 8) were 
examined. In both regions, the peptide agonist system had overall higher radius gyration 





Figure 13. Radius gyration of peptide agonist and small molecule antagonist. Used to 
determine average size in angstroms of N-terminal region (left) and C-terminal region 
(right) of the receptor for the peptide agonist and small molecule antagonist systems. 
Blue = peptide agonist system, red = small molecule antagonist system.  
 
2.3.7 Trajectory clustering analysis revealed three molecular switches. 
Molecular switches are conformational changes induced by non-covalent interactions that 
cause the molecule to enter an activated state18. We were able to examine these molecular 
switches by superimposing the agonist and antagonist complexes of their most abundant 
cluster. In total, three molecular switches were studied: the Ionic lock, the Polar lock, and 
the Rotamer Toggle switch25. The ionic lock, located between Arg180 and Glu238, was 
shown to be formed in both systems (Figures S9 and S10). To test whether the Ionic 


























distance (Å) versus time (ns) for the entire run. The graph clearly shows that the lock 
remains unbroken for the entire simulation. The polar lock, located between His180 and 
Glu238, appears to be broken in the agonist, but at least partially formed in the antagonist 
(Figures 14 and 15). Matlab was again used to test the entire simulation. The resulting 
graph showed that the small molecule antagonist consistently maintained the bond while 
the peptide agonist fluctuated, but was broken for a majority of the simulation. The two 
systems showed a distinct rotational difference in the Rotamer Toggle switch located at 
residues Tyr356, Phe313, and Leu352 (Figure 16 and 17). Residues Tyr356 and Phe313 
showed the most rotational change. Leu352 showed little change between the two 
systems. We also examined a sequence motif GWGxP that is conserved among class B 
GPCRs to determine if it serves as a molecular switch in the activation of CRF1R. Little 









Figure 14. Polar lock in small molecule and peptide agonist. Displays location in 
reference to the transmembrane domain in both systems. Images taken from the first 
trajectory for the most abundant conformation obtained from trajectory clustering 
analysis. The Polar lock is located in the transmembrane domain on TM2 and TM3 at 
residues His155 and Glu209. See appendix A, Table 5 for generic numbering. Peptide 




































































































































































































































































































































































































































































































































































































































































































































Figure 15. Polar lock distances small molecule and peptide agonist for 3 trajectories. 
Data taken after 2000ns of simulation for all conformations for 3 trajectory simulations. 
Red = simulation trajectory 1, blue = simulation trajectory 2, green = simulation 
trajectory 3. Average distance for Agonist trajectory 1 = 6.87Å, trajectory 2 = 4.61 Å, 
trajectory 3 = 5.87 Å. Average distance for Antagonist trajectory 1 = 4.62 Å, trajectory 2 













Figure 16. Rotamer Toggle switch in peptide agonist and small molecule. Displays 
location in reference to overall receptor after 2000ns for the most abundant conformation 
obtained from trajectory clustering analysis. The Rotamer Toggle switch is located on 




















Figure 17. Rotamer toggle switch torsion angles for each residue. Depicts each residue 
Tyr356, Leu352, and Phe313 for both agonist and antagonist systems across 3 simulation 
trajectories. See appendix A, Table 5 for generic numbering. Red = simulation trajectory 















































2.3.8 Comparison to other GPCRs. Agonists appear to adopt a relatively 
conserved conformation to allow for G protein docking (Figure S12). After 
superimposing our agonist system on other G protein docked GPCRs, it was revealed that 
our agonist system adopts this same conformation. The c-terminal end opens up and the 
intracellular side of the transmembrane domain spreads to allow space for the G protein 
to dock. In our antagonist system, the c-terminal end uncoils and angles downward as 
well as the intracellular side of the transmembrane domain not spreading outward 
(Figure 18, 19, S13-S25). This would close off the site and prevent G protein docking as 




Our Peptide Agonist 
System 






Figure 18. Comparison between our peptide agonist complex and the solved structure of 
the G protein docked Glucagon-like-peptide 1 receptor. Structure obtained from 
obtained from PDB 6B3J. Top panels compare the full receptor and bottom panels 
compare the C-terminal helices.  











           
Figure 19. Comparison between our small molecule antagonist complex and the solved 
structure of the G protein docked Glucagon-like peptide-1 receptor. Structure obtained 
from PDB 6B3J. Top panels compare the full receptor and bottom panels compare the C-





















The CRF1 receptor is a good drug target for stress related issues such as 
depression, inflammation, and anxiety. A lack of FDA approved drugs targeting this 
receptor is due to a lack of knowledge on how class B GPCRs activate as well as a lack 
of a high resolution crystal structure for CRF1R bound to its peptide hormone. This makes it 
difficult to create ligands that are selective to only this receptor. Several previous studies have 
examined the CRF1 receptor binding to small molecule antagonist ligands,22, 25, 40 but there is a 
lack of studies on CRF1 bound to peptide ligands. Seidal20 gained insight into the conformational 
differences between bound peptide agonist and peptide antagonist structures, but more studies 
need to be performed to gain a better understanding of the activation mechanisms. In our study, 
we examined how CRF1R interacts with a peptide agonist and a small molecule antagonist and 
propose key conformations and molecular switches that may play a role in the activation of the 
receptor. We develop a new possible mechanism of activation focusing less on molecular 
switches as previous studies have done.  
Since there was no complete homology model for the CRF1R in the protein 
database, one had to be created. I-TASSER was used to create the homology model and 
did so using the top ten PDB templates for threading (Table S1). TASSER provided 
several possible models. The model we selected was the one that prioritized PDB 4K5Y 
because 4K5Y is the crystal structure of inactivated CRF1R, without the extracellular 
domain. This model would allow us to determine the effects that our ligands have on the 
activation of the receptor. We compared this model to the crystal structure for the 
transmembrane domain (PDB ID: 4K5Y) and extra cellular domain (PDB ID: 3EHU) in 
figure 2. This generic pose was used as the starting position, which quickly changed 
conformation upon docking of the ligands. Since 4K5Y contains the docked ligand CP 
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376395, this was used to justify our docking orientation. The justification of our docking 
orientation for the peptide ligand comes from PDB 5NX2 which docked a truncated 
peptide with the GLP-1 receptor (figure S4). The N-terminal region was placed in the 
binding pocket and the C-terminal region was oriented to interact with the extracellular 
domain. In terms of overall conformational change, distinct formations were associated 
with whether the protein-ligand complex was agonized or antagonized. We compare the 
conformational difference of each region of interest (extracellular domain, 
transmembrane domain, and helix 8) in figure 5. For the extracellular domain, the agonist 
conformation bends outward, opening up the transmembrane region for activation while 
the antagonist conformation maintained a vertical formation, closing off and preventing 
activation of the receptor. Our RMSD data in figure 4 further makes the distinction 
between agonist and antagonist conformations. The transmembrane region is more fully 
analyzed in figure 6. The conformational shift is very distinct in helices 1, and 5-7 
between agonist and antagonist structures. Another important conformational difference 
was in helices 8. The agonist had a more rigid helix 8 angled upward aiming at the 
extracellular domain. The antagonist showed to be in a more relaxed, uncoiled state and 
angled downward. This indicates that the conformational change in the extracellular 
domain in the agonist complex induces the activation of helix 8. 
We found that the peptide agonist and small molecule antagonist experience 
different types of protein-ligand interactions. Figure 7 depicts which residues are 
interacting with each other and what type of interaction there is for the agonist system. 
There are primarily hydrogen binding and van der Waals interactions, but notably there 
are two salt bridges that form in the agonist system which do not appear in the antagonist 
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system. Figure 8 depicts the protein-ligand interactions that exist between the small 
molecule and the receptor. A notable difference here is the existence of a polar 
interaction with the small molecule that does not exist in the agonist system. These 
differences could contribute to the activation/deactivation of the receptor.  
Our secondary structure data in figure 9 summarizes structural differences 
between agonist bound and antagonist bound systems. Firstly, the extracellular domain of 
the agonist system display much more helical structure than in the antagonist system. The 
antagonist system also displays much more beta sheet structure in this region than the 
agonist system. This could indicate that helical structure in the extracellular domain is 
linked to activation and beta sheets are linked to inactivation. Also the secondary 
structure elements highlight the various kinks and shifts of the transmembrane region that 
we saw in figure 6. Finally, the C-terminal region was significantly less structured in the 
antagonist than in the agonist.  
Our data is also consistent with Seidal’s20 findings. He proposed that agonists 
adopt different folds than antagonists in order to stabilize the transmembrane domain. 
This difference occurs at TM 6 and 7 to produce a wide pose for agonists and a compact 
pose for antagonists. Our RMSF data in Table 1 and figure 10 shows that the E3 loop (the 
loop that connects TM 6 and 7) has a higher flexibility than any other region in the 
transmembrane domain. This high flexibility, along with the images we generated of the 
transmembrane region in figure S6, reinforces his findings that antagonists develop a 
compact pose and agonists develop a wide pose. Furthermore, our findings also indicate 
that the extracellular domain also plays a role in the development of these poses. The 
extracellular domain opens, activating helix 8 which spreads the receptor into its wide 
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pose. This is important to note because it could affect interaction with the G-protein, 
which we examine later on.  
Other important regions to look at when examining activation are molecular 
switches, conformational changes induced by non-covalent interactions. The three 
molecular switches we focused on were the ionic lock, polar lock, and rotamer toggle 
switch which Xu identified as being likely linked to activation25. The ionic lock, located 
between TM2 and TM3 at Arg151 and Glu209, (see appendix A, Table 5 for generic 
numbering) was formed in the small molecule antagonist and peptide agonist complexes. 
This indicates that this lock likely does not play an important role in the activation of the 
receptor (figure S9-S10). The Polar lock is located between TM2 and TM3 at residues 
His155 and Glu209. In their most abundant conformations, this bond is formed in the 
antagonist complex, but broken in the agonist complex suggesting that the formation of 
this bond could play a role in inhibiting this receptor (figure 13-14), however it not 
believed to be a major contributor due to high variation in distance lengths. After running 
three separate trajectories, the polar lock ranges from 4 to 9Å in varying durations in the 
agonist system and remains fairly constant at 4Å in the antagonist (figure S29 and S54). 
The last molecular switch we looked at was the rotomer toggle switch located between 
TM5 and TM6 at Phe284, Leu323, and Tyr327 (figure 15-16). We examined the different 
rotational differences of these residues and initially determined that the agonist 
complexes showed different torsions to the antagonist. Residues Phe313 and Tyr356 
show nearly a 180 degree rotational difference. However, inconsistencies were found 
after running three trajectories and it was determined that the rotomer toggle switch is 
relatively flexible in both agonist and antagonist systems (figures S30 and S56). The 
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GWGxP conserved sequence motif was also examined for differences between our two 
systems (figure S11). Xu25 concluded that it does not play a role in antagonist binding as 
there were no noticeable χ1 changes between the apo form and the antagonist bound 
form. Our results agreed with his conclusion. In our agonist bound model, there were also 
no noticeable changes, indicating that this conserved sequence also plays no role in 
agonist binding. Overall, it was determined that molecular switches, while likely 
contributing to activation, do not play as critical a role as originally thought.  
Most important to activation of the receptor is its ability to interact with the G-
protein. CRF1R interacts with a Gs protein (stimulating), so we found several receptors 
that have been docked to Gs protein in PDB for comparison. Upon superimposition of 
five different receptors, it was revealed that there is a high degree of conservation in the 
structure of the receptors to allow for docking of the G-protein. Our agonist and 
antagonist systems were then superimposed individually to each of the five receptors to 
gain insight into how our systems might interact with the G-protein. Our peptide agonist 
system adopted a similar conformation to all five receptors in comparison indicating that 
the peptide agonist signals for interaction with the G-protein. The key region to look at 
when making this claim is the C-terminal helix. The helix must undergo a conformational 
change to allow room for the G-protein to dock. We superimposed all C-terminal helices 
with our agonist system helix which showed that the agonist system forms a similar 
conformation. Furthermore, it was noted that the bottom region of the receptor also 
spreads itself, allowing for more room for the G protein. Our antagonist system does not 
match the others, indicating it does not allow for interaction with the G-protein. The C-
terminal helix becomes uncoiled and angles downward, causing a clash with the 
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superimposed G-proteins. This clash indicates that the helix would prevent the G-protein 
from being able to dock to CRF1R, thus preventing activation. The bottom region of the 
receptor also does not spread like the others do, further justifying the importance of this 
conformational shift. The large scale conformational changes associated with the 
transmembrane helices and helix 8 are believed to be the most important changes in 
receptor activation.  
2.5 Conclusions  
The CRF1 receptor would be a good drug target for conditions such as depression, 
anxiety, and inflammation since the receptor is associated with stress response. 
Unfortunately, there are not currently any FDA approved drugs that target this receptor 
due to a lack of a high resolution structure and understanding of the activation method. 
Previous studies on the CRF1R primarily focused on small molecule antagonist 
complexes, or distinguishing conformational differences between peptide agonists and 
peptide antagonists. We expand upon Seidel’s20 study by exploring conformational 
changes associated with CRF1R in complex with a peptide agonist (Urocortin), and small 
molecule antagonist (CP 154526). Previous studies on activation have focused on 
molecular switches. While likely a contributing factor, we propose that these molecular 
switches are not as critical as previously thought. We propose that activation is linked to 
large scale conformational changes associated with the transmembrane helices and the 
intracellular C-terminal helix. We first generated a homology model for CRF1R using I-
TASSER and compared to crystal structures from the Protein Data Bank (PDB 4K5Y and 
3EHU). The ligands were then individually docked to the receptor and subjected to a total 
of 4 µS (2 x 2 µS) molecular dynamics simulations, followed by trajectory clustering and 
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simulation interaction diagram analysis. Our RMSF data was consistent with Seidel’s20 
findings and we showed distinct conformational differences between agonist and 
antagonist complexes in the transmembrane domain, extracellular domain, and helices 8. 
Inconsistencies in our molecular switch data suggest that they play a far less significant 
role in activation than previously thought. Upon comparing our systems to other 
receptors, it was determined that they all adopt a conserved conformation to allow for G-
protein docking. One key aspect of this conformation is the C-terminal helix, which must 
angle out to allow space for the G-protein. Additionally, the bottom of the receptor must 
spread to help provide room for the G protein. Only our agonist system adopts these 
conserved conformation. Our findings point toward a new mechanism of activation and 





GLP-1 Receptor in Complex with a Full Agonist and a Biased Agonist Probed by 
Molecular Dynamics Simulations for the Development of more Specific Drugs on 
Type 2 Diabetes 
3.1 Introduction  
 3.1.1 G protein-coupled-receptors. The largest family of cell surface receptors 
are G protein-coupled-receptors (GPCRs). The general structure of a GPCR consists of 
an extracellular region, a transmembrane region composed of seven helices, and an 
intracellular C-terminus. Another defining characteristic of GPCRs is their ability to 
interact with G proteins to stimulate signaling pathways. GPCRs can be sub-classified 
into five groups, the largest of which is class A rhodopsin composed of over 700 
receptors. Other classes include class B secretin, class C glutamate, class D adhesion, and 
class E frizzled. Structural difference between these classes affect the ligand recognition 
mechanisms of the receptor and therefore affect their ability to transduce signals across 
the membrane19. Class B GPCRs are generally less understood when compared to class 
A, and were therefore chosen as the focus for this paper. A defining feature of class B 
GPCRs are their large extracellular domain which plays an integral role in ligands 
detection and binding. The extracellular domain specifically helps with peptide ligand 
binding. The C-terminal end of the peptide is first bound to the extracellular region which 
is used to guide the ligand into the binding pocket. This induces conformational changes 
to the receptor as a whole. Overall, there are 15 known class B GPCRs that control a 
number of functions in the body. They can be good drug targets to treat conditions 
ranging from diabetes to osteoporosis20.  
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 3.1.2 The glucagon-like-peptide receptor. The glucagon-like-peptide-1 receptor 
(GLP1R) is a class B GPCR that stimulates the secretion of insulin. It is primarily 
expressed in the pancreas, but can also be found in the heart and brain39. For this reason, 
the GLP1R is a good drug target for type 2 diabetes. Individuals with diabetes have 
problems maintaining insulin levels. Insulin is important for transporting glucose into 
your cells so they can be converted into energy. Type 1 diabetes is a condition in which 
the individual cannot produce their own insulin. Type 2 diabetes, often called adult onset 
diabetes and associated with obesity, is where the body is capable of producing its own 
insulin, but is not producing it in high enough concentrations. Developing drugs on this 
class of receptor to stimulant insulin secretion can help improve the lives of the many 








Figure 21. Snake plot of full-length human GLP1R. Data taken from GPCRdb23-24.  
 3.1.3 Full vs. biased agonsim. GPCR signaling mechanisms are not limited to a 
single pathway. There are several pathways that can be activated by a ligand, most 
notably the G protein pathway and the β-arrestins pathway. Full agonist ligands activate 
the whole receptor and all signaling pathways associated with it. Drugs modeled after full 
agonists can have inadvertent side effects due to this unspecific signaling pathway. 
Biased agonism is where the ligand is specific to one particular signaling pathway. If the 
activation mechanism of biased agonism can be more fully understood, drugs can be 
developed to be specific to one pathway therefore reducing the amount of side effects the 
drug causes. In this study, we examine exendin-P5 (ExP5) which has been shown to be 
biased to the G protein pathway38.  
 3.3.4 Experimental overview. Here we explore the conformational changes 
associated with the GLP1 receptor bound to a full agonist (truncated GLP1 peptide PDB 
ID: 5NX2) and a biased agonist (ExP5 PDB ID: 6B3J) to develop a more detailed 
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understanding of the activation mechanism of biased agonists. Molecular dynamics 
simulations were performed on these systems as well as the unbound form (APO) and 
analyses were performed. Analyses include simulation interaction diagram, trajectory 
cluster analysis, and MMGBSA analysis. Our findings help to elucidate the activation 
mechanism of biased agonists which can lead to the development of more specific drugs 
for the treatment of type 2 diabetes.  
 
3.2 Methods 
3.2.1 Protein and Ligand Preparation: The structure of the GLP1 receptor was 
obtained from the protein data bank (PDB) from PDB ID: 5NX2. The full agonist ligand 
was also obtained from this entry and the biased ligand was obtained from PDB ID: 
6B3J. Maestro’s Protein Preparation Wizard27 was used to prepare the models for 
docking. Operations performed included a preprocessing step which added hydrogens 
where appropriate, corrected bond orders, and removed water where appropriate. This 
was followed by a charge state optimization and then a restrained minimization.  
3.2.2 Docking: Maestro’s Glide Docking feature was used to dock the ligands to 
the receptor. To do this, a grid is first generated and the ligands and receptors are 
specified. The biased agonist was docked using standard precision peptide mode (SP-
peptide) in an OPLS3 field. The peptide was oriented such that the C-terminal end 
interacts with the extracellular domain (ECD) and the N-terminal end interacts with the 
binding pocket31-32. The truncated peptide full agonist was small enough the Maestro was 
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able to detect it as a small molecule ligand and was therefore docked using extra 
precision (XP) mode.  







Figure 22. Docked full agonist (red) and biased agonist (green). Ligands docked into the 




3.2.3 Molecular Dynamics Simulations: Three systems, full agonist docked, 
biased agonist docked, and APO form were run under molecular dynamics (MD) 
simulations. Systems were aligned in a membrane which was set to the helices of the 
transmembrane region. They were then solvated in a water box using the SPC water 
model. 0.15M NaCl was added to help neutralize the system. The Desmond System 
Builder in Maestro was used to generate an OPLS3 force field to build these systems. 
MD simulations ran for a total of 6 µS (2 µS per system). 
3.2.4 Trajectory Clustering Analysis: The structures of the final 100ns of each 
simulation was grouped using the Desmond trajectory tool. The structural similarity 
metric selected was backbone RMSD and average linage was selected for hierarchical 
clustering. Merging distance cutoff was set to 2.5 Å. Frequency was set to 2. The number 
of frames was set to 250. Number of threads was set to 2. Structures who showed a 
frequency greater than 2% were saved for further analysis. The most abundant cluster for 
each system was aligned and superimposed to compare structural differences in the ECD, 
transmembrane domain (TMD), and C-terminal helix 8.  
3.2.5 Simulation Interaction Diagram (SID) Analysis: Maestro’s SID tool is 
used to analyze interactions between the protein and ligand. SID includes Root Mean 
Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), secondary structure 
analysis, and protein-ligand interactions. RMSD measures the displacement change of 
atoms for the entire trajectory with respect to the reference frame and is calculated using 





RMSF analyzes changes along a protein chain or molecule. The RMSF equation used for 
this calculation is shown below where T is the trajectory, t is time, r is residue positon, 
and the < and > signs indicate that the average of the square distance is taken.  
 
Secondary structures are monitored for the entire trajectory. Alpha-helical structures and 
beta strands can be observed as well as kinks that develop over time. SID also analyzes 
the types of protein-ligand interactions that occur over time (i.e. H-bonds, van der Waals, 
etc.).  
3.2.6 Comparison to other GPCRs: Five different complexes were taken from 
the Protein Data Bank (PDB IDs: 6b3j38, 5uz737, 5vai36, 5g5335, 3sn634) that were docked 
to the G protein. Each complex was aligned with our systems individually and 
superimposed within Maestro to examine our systems ability to interact with the G 
protein. Comparisons were also made to a beta arrestin bound GPCR (PDB ID: 4zwj41). 
Structures were aligned in Maestro and optimized in VMD.  
3.2.7 MMGBSA Analysis: MMGBSA was used to calculate binding energies of 
the last 100 ns of each system. The default procedures were used when preforming this 
analysis. First the receptor was minimized, then the ligand was minimized, followed by a 
receptor-ligand complex minimization. The equation for total binding free energy is: 




3.3.1 Conformational differences between full and biased agonist systems. 
There were three regions which showed conformational differences which include the 
ECD, TMD, and the C-terminal helix. In the most abundant conformation, obtained from 
the trajectory clustering analysis, the full agonist showed the ECD tilted toward the right 
(Figure 24). The TMD showed a shift in helices focusing on the intracellular region. The 
region appears to have spread and opened up, which is typical of agonists. The C-
terminal helix angled out and also seemed to spread. For the APO form, the ECD 
maintained a more vertical conformation. The TMD and C-terminal helix did not spread 
and remained closed off. The biased system’s ECD was more vertical than the APO form, 
but not as tilted as the full agonist complex. The TMD maintained an open, yet narrower, 
conformation and the C-terminal helix inverted and angled inward. Our RMSD data 
shows that both biased and APO systems stay within a certain range once they level off. 
The full agonist system levels off quickly, but jumps up toward the end of the simulation 




Figure 23. Root Mean Square Deviation (RMSD). Full unbiased agonist (left), biased 
agonist (right), APO form (bottom). Used to measure the average change in displacement 
of a selection of atoms for a particular frame with respect to a reference frame. It is 










































Figure 24. Most abundant conformations. Pairwise comparison of the most abundant 
conformations for full agonist system (red) and biased agonist system (green) obtained 
from the trajectory clustering analysis. Comparisons broken down into key regions: 
TMD, ECD, C-terminal, and ligand.  
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3.3.2 Different types of protein-ligand interactions. Overall, the biased agonist 
had more interaction with the receptor since it was a much larger molecule. The full 
agonist ligand experienced predominantly hydrophobic, polar, and charged reactions, but 
also experienced salt bridges and pi-stacking. The biased ligand most predominantly 
experienced hydrophobic interactions, but also experienced polar, charged, salt bridges, 









3.3.3 Secondary structures revealed differences among the three systems. The 
full agonist and biased agonist systems showed very similar secondary structures for the 
whole simulation. The major difference appears in the C-terminal helix 8. The biased 
system shows significantly less helical structure then the full agonist system. The APO 











Figure 26. Secondary structure elements (SSE). Comparison for full agonist, biased 
agonist, and APO systems. Orange = alpha helices, blue = beta sheets. Key structural 


















































































































































































































































































































































































































































































































































































3.3.4 The protein RMSF data showed different fluctuation levels. The full 
agonist system overall had the highest RMSF values. The APO form overall had the 
lowest RMSF values, however certain regions of the biased system had lower RMSF then 
the APO. These regions include the extracellular loops and the transmembrane helices 
(Table 1). This comparison is visualized in figure 27. 
Table 3 
Mean values (Å) for the RMSF of each portion of the ligand-receptor complexes.  
Domain Full Ago 
Apo Biased 
Ago 
N-terminal 3.62 2.75 2.67 
TM1 2.40 1.75 1.14 
I1 3.62 1.76 2.74 
TM2 2.35 1.60 1.20 
E1 3.02 2.19 1.83 
TM3 1.57 1.46 1.33 
I2 3.82 2.17 2.90 
TM4 1.99 1.47 1.28 
E2 2.57 1.97 1.63 
TM5 2.10 1.93 1.72 
I3 5.85 3.79 6.00 
TM6 4.11 1.81 2.94 
E3 2.40 2.56 1.98 
TM7 1.88 1.67 1.09 
C-terminal 3.95 2.87 3.33 
All I’s 4.43 2.58 3.88 
All E’s 2.66 2.24 1.81 
All Loops 3.55 2.41 2.85 
All TM’s 2.34 1.67 1.53 





Figure 27. Cα Root Mean Square Fluctuation (RMSF) of all three systems. Used to 
determine flexibility of each region throughout the simulation.  
 
3.3.5 Comparison to solved GPCRs provided insight into biased activation. 
Several solved G protein docked GPCRs (PDB IDs: 6b3j, 5uz7, 5vai, 5g53, 3sn6) were 
aligned and superimposed with our systems in maestro. The full agonist system adopted a 
very similar conformation to the solved structures. The ECD folded in the same direction, 
the TMD spread in a similar fashion, and the C-terminal helix moved to a similar 
conformation (Figure 28). The Biased agonist system adopted a different conformation 
then the solved structures. The ECD was more vertical, the TMD showed less spreading 
but angled out, and the C-terminal helix inverted in on itself to face the other way. With 
all these changes, the biased system still does not clash with the G protein (Figure 29). 

























































































































conformations and did not clash with the arrestin. The C-terminal helix of our biased 





Full Agonist System PDB ID: 6B3J Superimposition  
  
 
Figure 28. Comparison between our full agonist system aligned with the G-protein and 











Biased Agonist System PDB ID: 6B3J Superimposition  
   
Figure 29. Comparison between our biased agonist system aligned with the G-protein 
and the solved GLP1 receptor bound to the G-protein. Structure obtained from PDB 
















Full Agonist System PDB ID: 4ZWJ Superimposed 
 
  
Figure 30. Comparison between our full unbiased agonist system aligned with beta 
arrestin and the rhodopsin receptor bound to beta arrestin. Solved structure of the 





















Figure 31. Comparison between our biased agonist system aligned with beta arrestin and 
the rhodopsin receptor bound to beta arrestin. Solved rhodopsin receptor bound to beta 
arrestin (4zwj) obtained from PDB. The C-terminal helix of the biased system is circled 
in red. 
 
3.3.6 The biased agonist bound more stably then the full agonist. Table 2 
summarizes the average MMGBSA values and standard deviations of the two systems. 
Three categories were calculated from the outputted data from the MMGBSA analysis: 
van der Waals (VDW), electrostatic (ELE), and hydrophobic. These values were totaled 
up to give total binding energy. The biased system experienced more stable binding in 







MMGBSA binding values for full agonist and biased agonist systems.  
 VDW ELE Hydrophobic Total 
Full Ago -121 + 7.94 -80.1 + 27.9 -99.6 + 6.77 -300 + 33.7 
Biased Ago -211 + 15.7 -226.1 + 51.4 -147.9 + 9.13 -585 + 51.6 
Average MMGBSA values for both systems. Values are measured in kcal/mol. VDW = Van der 
Waals, ELE = electrostatic.  
 
3.4 Discussion 
 The GLP1 receptor is a good drug target for type 2 diabetes because it controls 
insulin secretion. Individuals inflicted with type 2 diabetes are incapable of producing a 
sufficient amount of insulin required by their body. For this reason, agonist drugs can be 
used on the GLP1 receptor to raise insulin levels. However, current agonists used are full 
agonists, meaning they activate all signaling pathways of GLP1R. This could lead to the 
drug causing unwanted side effects due to not being specific for the desired pathway. A 
more suitable drug molecule would be a biased agonist, specifically one that is biased 
toward the G protein pathway. Unfortunately the mechanism of action of biased agonists 
are poorly understood. In this study, we aim to develop a more detailed understanding of 
this activation mechanism so that future drugs on this receptor will be more efficient and 
have less side effects. We propose that the key conformational change associated with 
biased agonism lies in the way the intracellular region opens to allow for G protein 
docking. Specifically, a conformational change in the C-terminal helix could play the 
most important role in biased activation.  
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 The structure for GLP1R was obtained from the Protein Data Bank (PDB) from 
PDB ID 6b3j. The full agonist we used was a truncated GLP1 hormone which was 
obtained from PDB ID 5nx2. The biased agonist we used exendin-P5, which was known 
to be biased toward the G protein pathway, was obtained from PDB ID 6b3j. Ligands 
were docked to the receptor (Figure 22) and then run under MD simulations for 2µs each. 
An APO form (receptor only) was also examined under MD simulations for comparison 
purposes. Upon inspection of the most abundant conformation that resulted from these 
simulations, distinct conformational differences were observed (Figure 24). As expected, 
the full agonist system showed a wide spreading of the intracellular region to allow room 
for G protein docking. The APO form also behaved as expected and did not show this 
characteristic spreading and even appeared to close off slightly. This would indicate an 
inability to bind to the G protein. The biased system displayed a very interesting 
structure. The intracellular region formed a more compact pocket for the G protein. Most 
interesting is the conformation of the C-terminal helix. Instead of spreading outward like 
the full agonist system, it inverted and flipped directions. When we compared our 
structures to docked G protein complexes (Figures 28 and 29), it was revealed that these 
conformational differences do not clash with the G protein. It was therefore theorized that 
this compact opening of the intracellular region combined with the inverted C-terminal 
helix conformation are responsible for the specificity toward the G protein pathway. 
When compared to structures docked to beta arrestin proteins (Figures 30 and 31) this 
was confirmed showing a clash between the C-terminal helix in the biased system with 
the arrestin protein. The full agonist system did not show any clashes indicating it is full 
capable of binding.  
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 Our RMSD data supports what we see from the MD simulations (Figure 23). For 
the full agonist, we see relatively constant values until the end of the simulation where we 
see a sharp spike. This spike is indicative of the spreading of the intracellular region. The 
RMSD data for the full agonist ligand shows that is remains fairly constant throughout 
the simulation. For the biased system, we were only able to do a protein only analysis due 
to limitations with Maestro’s SID tool. The receptor complex fluctuates between 3 and 5 
Å throughout the simulation, and becomes more rigid toward the end. The APO form as 
expected showed the least amount of deviation once it reached equilibrium. The tighter 
conformation of the biased system can be attributed to how tight the receptor binds to the 
ligand. There are significantly more protein-ligand interactions acting on the biased 
ligand then the full agonist ligand (Figure 25). This is due largely to the much greater size 
of the biased ligand. The MMGBSA results further confirm these conclusions. The total 
MMGBSA value for the biased system is almost twice as energetically favorable when 
compared to the full agonist which indicated greater stability (Table 4).  
 Our secondary structure elements graph (Figure 26) further clarifies 
conformational differences. The full agonist and biased agonist systems showed very 
similar levels of alpha helices and beta sheet formation. This was expected as both 
ligands are known agonists. Minor deviations can be seen in TM5 and TM6, but the most 
critical difference is in helix 8 (C-terminal helix). This change is attributed with the 
conformational flip in the biased system. Our RMSF data in figure 27 and table 3 
elucidates further on the movement of the receptors. The full agonist system showed the 
highest overall RMSF values, which agrees with our MD simulation results since it 
observed the greatest conformational change. The APO form showed the overall lowest 
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RMSF values indicating the lowest amount of conformational change. This agrees with 
our MD results and was the expected outcome due to not being bound to a ligand. The 
biased system overall showed RMSF values in between these two systems, but important 
regions to note are the high RMSF values at the C-terminal region as well as intracellular 
loop 3. This coincides with our hypothesis that these conformational differences are 
critical in the activation mechanism of biased agonists.  
 The full agonist system was shown to adopt similar conformations to solved 
structures and did not clash with the G protein, indicating it is able to bind to the G 
protein. When compared to arrestin bound GPCRs, it is still found to not clash, indicating 
an ability to bind to arrestin protein as well. We can then link this general wide spreading 
of the receptor to correspond with full agonism. Our biased system was shown to not 
clash with the G protein, indicating an ability to bind to it. Its C-terminal helix however 
was shown to clash with the arrestin protein, indicating it does not bind to beta arrestin. 
The conformational change of the C-terminal helix can then be attributed to blocking 
arrestin binding. This agrees with information found in the literature41-44. When a G 
protein docks to a receptor, it hangs off to one side. A docked arrestin is more centered 
underneath the receptor and has a helical structure pointing out the top end. Our results 
show that the wide spread that we observe in the full agonist system is general enough to 
accommodate both types of signaling molecules. Since the biased system remains more 
compact, this forces the signaling molecule to dock off-centered. This allows the G 
protein to still be able to dock, while at the same time prevents the arrestin from binding 
since it no longer has the room to dock directly underneath the receptor. The C-terminal 
helix plays the most important role in this mechanism since the inversion of the helix 
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allows for interaction with the G protein, but blocks the site for the arrestin protein by 




3.5 Conclusion  
 The GLP1 receptor is a class B GPCR whose main function is to stimulate insulin 
secretion. For this reason, GLP1 is a good drug target for treating type 2 diabetes, which 
is the condition in which the body cannot produce a sufficient amount of insulin to allow 
glucose to enter the cells. To treat this, agonist compounds can be used to stimulate the 
production and secretion of more insulin. However, most agonists are not specific to just 
one pathway and therefore can be associated with side effects. Special types of agonists 
called biased agonists are specific to one pathway, and would therefore lower the amount 
of side effects and improve the drug. Unfortunately, an understanding of the mechanism 
of activation of biased agonists remains elusive. The goal of this study was to develop a 
more detailed understanding of biased agonism so that improved, more specific drugs can 
be developed. Our studies have shown distinct conformations of the intracellular region 
of the receptor and the C-terminal helix that we propose to play a critical role in biased 
activation. We set up three systems for comparison: a full agonist, biased agonist, and 
APO form system. All complexes were run under MD simulations for 2µs and trajectory 
clustering analysis was performed to determine the most abundant conformation. It is 
here that we visually saw the conformational differences between the two systems. The 
full agonist spread wide enough to allow for G protein docking which also supported 
docking of beta arrestins indicating activation of both signaling pathways. The biased 
system formed a more compact conformation and observed a critical helical switch of the 
C-terminus. The C-terminal helix conformation allowed for G protein activation, but 
blocked the arrestin protein from binding indicating it only activates the G protein 
signaling pathway. Simulation Interaction Diagram analyses were also performed to 
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determine protein-ligand interactions, RMSD, RMSF, and secondary structure elements, 
all of which supported our hypothesis. Finally, MMGBSA analysis was performed to 
measure the binding affinity of the two ligands. It was determined that the biased ligand 
bound much more stability, further enticing the development of drugs of this class. Future 
studies can test other receptors and other ligands to confirm that these conformations are 
conserved. Our findings provide insight into developing a new, more efficient class of 
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Binding of Peptide Agonist Urocortin and Small Molecule Antagonist CP 376395 to 
the CRF1 Receptor Probed by Molecular Dynamics Simulations 
 
Table A1 














5vai R Activated Glucagon-like peptide-
1 receptor 
0.28 0.29 0.84 1.95 
2 
5vai 
A Activated Glucagon-like peptide-
1 receptor 
0.28 0.29 0.83 3.91 
3 
5vai 
R Activated Glucagon-like peptide-
1 receptor 
0.27 0.29 0.83 2.86 
4 4l6r A Class B human glucagon GPCR 0.28 0.27 0.82 3.02 
5 
4k5y 
A CRF1R in complex with 
antagonist 
0.84 0.54 0.56 3.20 
6 4l6r A Class B human glucagon GPCR 0.23 0.27 0.89 3.38 
7 4l6r A Class B human glucagon GPCR 0.27 0.27 0.81 4.29 
8 4l6r A Class B human glucagon GPCR 0.33 0.23 0.65 2.56 
9 
5vai 
9 Activated Glucagon-like peptide-
1 receptor 
0.28 0.29 0.84 2.54 
10 
5nx2 
A GLP-1R with a truncated peptide 
agonist 
0.27 0.26 0.84 1.79 
       
(a) Rank of template represents top ten threading templates used by GPCR-I-TASSER 
(b) Iden1 is the percentage sequence identity of the templates in the threading aligned 
region with the query sequence. 
(c) Iden2 is the percentage sequence identity of the whole template chains with query 
sequence. 
(d) GPCR is the type of G-protein-coupled-receptor correlating to the PDB ID. 
(e) Cov. Represents the coverage of the threading alignment and is equal to the number of 
aligned residues divided by the length of query protein.  
(f)Norm. Z-score is the normalized Z-score of the threading alignments. Alignment with 













Figure A1. Docked peptide agonist urocortin and small molecule antagonist CP 376395 








































































































































































































































































































































































































































































































































































































































































































































































































   
Figure A2. Pairwise comparison between crystal structures of CRF1R (ECD from PDB 
3EHU and TMD from PDB 4K5Y) and our generated model for the CRF1 receptor from 
TASSER.  
 





































CRF1 GLP1 Superimposition  
 
      
 
       
 
Figure A3. Structural similarity comparison between GLP1 structure (PDB 6B3J) 































Figure A4. Comparison of CRF1R transmembrane domain bound to a peptide agonist 
and antagonist with GLP1 bound to a truncated peptide agonist. Peptides are denoted in 
yellow. The green tips on the CRF peptides denote the C-terminal end of the peptide. The 























































































































































































































































































































































































Peptide agonist Small molecule antagonist 
 
 
Figure A6. Comparison between wide pose observed in agonist systems and compact 
pose observed in antagonist systems. Highlighted are TM 6 and 7 to examine whether the 





Figure A7. Ligand-protein interactions for peptide agonist system. Residues listed on the 
graph are the residues located on the receptor. Residues that interact with the peptide are 



























Residues on the CRF1 Receptor Interacting with Peptide 
Agonist 




Figure A8. Ligand-protein interactions for peptide agonist system. Residues listed on the 
graph are the residues located on the ligand. Residues that interact with the peptide are 







































Residues on Peptide Ligand Interacting with the CRF1 
Receptor










Figure A9. Ionic lock location in reference to the transmembrane domain in peptide 
agonist and small molecule antagonist systems after 2000ns for the most abundant 
conformation. Images were taken from the first simulation trajectory. The ionic lock is 
located on TM2 and TM3 at residues Arg151 and Glu209. Peptide Agonist distance = 


































































































































































































































































































































































































































































































































































































































































































































Figure A10. Ionic lock distances in small molecule and peptide agonist after 2000ns for 
the first simulation trajectory used for a preliminary analysis. Average distance of the 












































































































Figure A11. Comparing the GWGxP conserved motif in the agonist and antagonist 
systems for structural differences. It is located on TM4 between residues G235, W236, 
















GPCR PDB IDs 




Adenosine A2A receptor 
5uz7 Calcitonin receptor 
5vai Glucagon-like peptide-1 receptor 






































3sn6 5g53 5uz7 5vai 6b3j All 
 






   
 
 
Figure A12. Comparison of different G-protein docked gpcrs. A-E) Red = 
transmembrane domain, magenta = C-terminal helix, white = alpha subunit of g protein, 
black = beta subunit of g protein, green = gamma subunit of g protein, yellow = 





























































































































































































































































Our agonist/antagonist transmembrane domain 
Our agonist/antagonist C-terminal helix 
Orange Peptide agonist ligand 
Red GPCR transmembrane domain 
Magenta  GPCR C-terminal helix 
White Alpha subunit of G protein 
Black Beta subunit of G protein 






























Figure A13. Comparison between our peptide agonist complex and the solved structure 
of a G protein docked Adrenergic receptor obtained from PDB. Top panels show the 
whole receptor complex, bottom panels show the C-terminal helix.   
 
  












Figure A14. Comparison between our peptide agonist complex and the solved structure 
of a G protein docked Adenosine A2A receptor obtained from PDB. Top panels show the 




























Our Peptide Agonist System PDB ID: 5UZ7 Superimposition  




Figure A15. Comparison between our peptide agonist complex and the solved structure 
of G protein docked Calcitonin receptor obtained from PDB. Top panels show the whole 




































Figure A16. Comparison between our peptide agonist complex and the solved structure 
of G protein docked Glucagon-like peptide-1 receptor (5vai) obtained from PDB. Top 





























Figure A17. Comparison between our peptide agonist complex and the solved structure 
of G protein docked Glucagon-like peptide-1 receptor (6b3j) obtained from PDB. Top 
panels show the whole receptor complex, bottom panels show the C-terminal helix.   
  
  








3sn6 5g53 5uz7 5vai 6b3j All 






Figure A18. Comparison of the C-terminal helices of the solved structures from figures 



















      
         
Figure A19. Comparison between our small molecule antagonist complex and the solved 
structure of G protein docked Adrenergic receptor obtained from PDB. Top panels show 
the whole receptor complex, bottom panels show the C-terminal helix.  The C-terminal 









































     
        
Figure A20. Comparison between our small molecule antagonist complex and the solved 
G protein docked Adenosine A2A receptor obtained from PDB. Top panels show the 
whole receptor complex, bottom panels show the C-terminal helix. The C-terminal helix 








































      
        
Figure A21. Comparison between our small molecule antagonist complex and the solved 
G protein docked Calcitonin receptor obtained from PDB. Top panels show the whole 
receptor complex, bottom panels show the C-terminal helix. The C-terminal helix is 











































      
          
Figure A22. Comparison between our small molecule antagonist complex and the solved 
structure of G protein docked Glucagon-like peptide-1 receptor (5vai) obtained from 
PDB. Top panels show the whole receptor complex, bottom panels show the C-terminal 





































           
Figure A23. Comparison between our small molecule antagonist complex and the solved 
structure of G protein docked Glucagon-like peptide-1 receptor (6b3j) obtained from 
PDB. Top panels show the whole receptor complex, bottom panels show the C-terminal 
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Figure A24. Comparison of C-terminal helices from the solved structures from figures 
S19-S23 with the C-terminal helix from our small molecule antagonist system (shown in 












       
Figure A25. Comparison between our peptide agonist complex and small molecule 
antagonist complex bound to the G-protein, specifically looking at the C-terminal helix 8 
show in red in panels 1 and 2. Panel 3 shows a superimposed comparison of the two 
complete systems. Panel 4 and 5 shows the agonist and antagonist C-terminal helices 
individually. Panel 6 compares the C-terminal helices superimposed.  
1 2 3 






Pairwise comparison of peptide agonist and other GPCRs 
 
 
   
Pairwise comparison of small molecule antagonist and other GPCRs 
 
     
 
   
Figure A26. Pairwise comparison between our systems and the five systems from figure 
18. Blue = transmembrane domain of our system, cyan = helix 8 from our system, red = 
other transmembrane domain, magenta = other helix 8, white = alpha component of G 
protein, black = beta component of G protein, green = gamma component of G protein, 
yellow = nanobody on G protein. A) Our peptide agonist system compared to PDB entry 
3sn6. B) Peptide agonist compared to PDB entry 5g53. C) Peptide agonist compared to 
PDB entry 5uz7. D) Peptide agonist compared to PDB entry 5vai. E) Peptide agonist 
compared to PDB entry 6b3j. F) Our small molecule antagonist system compared to PDB 
entry 3sn6. G) Small mollecule system compared to PDB entry 5g53. H) Small molecule 
compared to PDB entry 5uz7. I) Small molecule compared to PDB entry 5vai. J) Small 








































































































































































































































Figure A27. Comparison of secondary structural elements between the three simulation 
trajectories of the peptide agonist system. Orange = alpha helical structure, blue = beta 
sheets. N-terminal region: 0-145, TM1: 146-170, TM2: 178-205, TM3: 215-248, TM4: 
255-281, TM5: 298-330, TM6: 339-362, TM7: 370-395, C-terminal region: 396-444. 





Figure A28. Comparison of the polar lock distances of the first trajectory for agonist and 





Figure A29. Comparison of the ionic lock distances in angstroms across all three 
simulation trajectories for 2000ns. Average distance for the 1st simulation = 3.94Å, 2nd 












Figure A30. Comparison of the rotamer toggle switch rotational differences of each 



































Figure A31. Comparison between our second trajectory peptide agonist complex and the 
solved structure of G protein docked Glucagon-like peptide-1 receptor (6b3j) obtained 











Figure A32. Comparison between our second trajectory peptide agonist complex and the 
solved structure for G protein docked Adrenergic receptor obtained from PDB. Top 











Figure A33. Comparison between our second trajectory peptide agonist complex and the 
solved structure for G protein docked Adenosine A2A receptor obtained from PDB. Top 









Figure A34. Comparison between our second trajectory peptide agonist complex and the 
solved structure for G protein docked Calcitonin receptor obtained from PDB. Top panels 











Figure A35. Comparison between our second trajectory peptide agonist complex and the 
solved structure for G protein docked Glucagon-like peptide-1 receptor (5vai) obtained 









Figure A36. Comparison between our third trajectory peptide agonist complex and the 
solved structure for G protein docked Glucagon-like peptide-1 receptor (6b3j) obtained 













Figure A37. Comparison between our third trajectory peptide agonist complex and the 
solved structure for G protein docked Adrenergic receptor obtained from PDB. Top 




Our Peptide Agonist System PDB ID: 5G53 Superimposition  
   
  
 
Figure A38. Comparison between our third trajectory peptide agonist complex and the 
solved structure for G protein docked Adenosine A2A receptor obtained from PDB. Top 











Figure A39. Comparison between our third trajectory peptide agonist complex and the 
solved structure for G protein docked Calcitonin receptor obtained from PDB. Top panels 










Figure A40. Comparison between our third trajectory peptide agonist complex and the 
solved structure for G protein docked Glucagon-like peptide-1 receptor (5vai) obtained 












   
Figure A41. Comparison between all three trajectories of our peptide agonist systems 




Our Antagonist System PDB ID: 6B3J Superimposition  
 
  
   
Figure A42. Comparison between our second trajectory small molecule antagonist 
complex and the solved structure of G protein docked Glucagon-like peptide-1 receptor 
(6b3j) obtained from PDB. Top panels show the full complex, bottom panels show the C-














Our  Antagonist System PDB ID: 3SN6 Superimposition  




Figure A43. Comparison between our second trajectory small molecule antagonist 
complex and the solved structure of G protein docked Adrenergic receptor obtained from 
PDB. Top panels show the full complex, bottom panels show the C-terminal helix. The 


















   
Figure A44. Comparison between our second trajectory small molecule antagonist 
complex and the solved structure for G protein docked Adenosine A2A receptor obtained 
from PDB. Top panels show the full complex, bottom panels show the C-terminal helix. 


















   
Figure A45. Comparison between our second trajectory small molecule antagonist 
complex and the solved structure for G protein docked Calcitonin receptor obtained from 
PDB. Top panels show the full complex, bottom panels show the C-terminal helix. The C-














Our  Antagonist System PDB ID: 5VAI Superimposition  
 
  
   
Figure A46. Comparison between our second trajectory small molecule antagonist 
complex and the solved structure for G protein docked Glucagon-like peptide-1 receptor 
(5vai) obtained from PDB. Top panels show the full complex, bottom panels show the C-














Our Antagonist System PDB ID: 6B3J Superimposition  
 
  
   
Figure A47. Comparison between our third trajectory small molecule antagonist complex 
and the solved structure for G protein docked Glucagon-like peptide-1 receptor (6b3j) 
obtained from PDB. Top panels show the full complex, bottom panels show the C-




















Figure A48. Comparison between our third trajectory small molecule antagonist complex 
and the solved structure for G protein docked Adrenergic receptor obtained from PDB. 
Top panels show the full complex, bottom panels show the C-terminal helix. The C-














Our Antagonist System PDB ID: 5G53 Superimposition  
   
   
Figure A49. Comparison between our third trajectory small molecule antagonist complex 
and the solved structure for G protein docked Adenosine A2A receptor obtained from 
PDB. Top panels show the full complex, bottom panels show the C-terminal helix. The 


















   
Figure A50. Comparison between our third trajectory small molecule antagonist complex 
and the solved structure for G protein docked Calcitonin receptor obtained from PDB. 
Top panels show the full complex, bottom panels show the C-terminal helix. The C-














Our Antagonist System PDB ID: 5VAI Superimposition  
 
  
   
Figure A51. Comparison between our third trajectory small molecule antagonist complex 
and the solved structure for G protein docked Glucagon-like peptide-1 receptor (5vai) 
obtained from PDB. Top panels show the full complex, bottom panels show the C-






















   
Figure A52.  Comparison between all three trajectories of our small molecule antagonist 


























Figure A53. Comparison of the secondary structural element between the three 
trajectories of the small molecule antagonists. Orange = alpha helical structures, blue = 
beta sheet formation. N-terminal region: 0-145, TM1: 146-170, TM2: 178-205, TM3: 
215-248, TM4: 255-281, TM5: 298-330, TM6: 339-362, TM7: 370-395, C-terminal 






Figure A54. Comparison of the polar lock distances in angstroms across all three 
antagonist trajectory simulations. Average distance of trajectory 1 = 4.62 Å, trajectory 2 





Figure A55. Comparison of the ionic lock distances across all three antagonist 
trajectories. Average distance for trajectory 1 = 3.90 Å, trajectory 2 = 3.84 Å, trajectory 3 











Figure A56. Comparison of the rotamer toggle switches torsion angles across all three 
antagonist simulation trajectories after 2000ns. Red = trajectory 1, green = trajectory 2, 






Generic numbering of residues for the CRF1R, Glucagon receptor, Oxytocin receptor, 





receptor Adrenoceptor  
Adenosine 
A2a 
TM1 TM1 TM1 TM1 TM1 
1x19 1x25 1x32 1x25 1x27 
1x20 1x26 1x33 1x26 1x28 
1x21 1x27 1x34 1x27 1x29 
1x22 1x28 1x35 1x28 1x30 
1x23 1x29 1x36 1x29 1x31 
1x24 1x30 1x37 1x30 1x32 
1x25 1x31 1x38 1x31 1x33 
1x26 1x32 1x39 1x32 1x34 
1x27 1x33 1x40 1x33 1x35 
1x28 1x34 1x41 1x34 1x36 
1x29 1x35 1x42 1x35 1x37 
1x30 1x36 1x43 1x36 1x38 
1x31 1x37 1x44 1x37 1x39 
1x32 1x38 1x45 1x38 1x40 
1x33 1x39 1x46 1x39 1x41 
1x34 1x40 1x47 1x40 1x42 
1x35 1x41 1x48 1x41 1x43 
1x36 1x42 1x49 1x42 1x44 
1x37 1x43 1x50 1x43 1x45 
1x38 1x44 1x51 1x44 1x46 
1x39 1x45 1x52 1x45 1x47 
1x40 1x46 1x53 1x46 1x48 
1x41 1x47 1x54 1x47 1x49 
1x42 1x48 1x55 1x48 1x50 
1x43 1x49 1x56 1x49 1x51 
1x44 1x50 1x57 1x50 1x52 
1x45 1x51 1x58 1x51 1x53 
1x46 1x52 1x59 1x52 1x54 
1x47 1x53 1x60 1x53 1x55 
1x48 1x54   1x54 1x56 
1x49 1x55   1x55 1x57 
1x50 1x56   1x56 1x58 
1x51 1x57   1x57 1x59 
1x52 1x58   1x58 1x60 
1x53 1x59   1x59 TM2 
133 
 
Table A5 (Continued) 
1x54 1x60   1x60 2x37 
1x55 TM2 TM2 TM2 2x38 
1x56 2x37 2x37 2x37 2x39 
1x57 2x38 2x38 2x38 2x40 
1x58 2x39 2x39 2x39 2x41 
1x59 2x40 2x40 2x40 2x42 
1x60 2x41 2x41 2x41 2x43 
TM2 2x42 2x42 2x42 2x44 
2x37 2x43 2x43 2x43 2x45 
2x38 2x44 2x44 2x44 2x46 
2x39 2x45 2x45 2x45 2x47 
2x40 2x46 2x46 2x46 2x48 
2x41 2x47 2x47 2x47 2x49 
2x42 2x48 2x48 2x48 2x50 
2x43 2x49 2x49 2x49 2x51 
2x44 2x50 2x50 2x50 2x52 
2x45 2x51 2x51 2x51 2x53 
2x46 2x52 2x52 2x52 2x54 
2x47 2x53 2x53 2x53 2x55 
2x48 2x54 2x54 2x54 2x551 
2x49 2x55 2x55 2x55 2x56 
2x50 2x56 2x56 2x551 2x57 
2x51 2x57 2x57 2x56 2x58 
2x52 2x58 2x58 2x57 2x59 
2x53 2x59 2x59 2x58 2x60 
2x54 2x60 2x60 2x59 2x61 
2x55 2x61 2x61 2x60 2x62 
2x56 2x62 2x62 2x61 2x63 
2x57 2x63 2x63 2x62 2x64 
2x58 2x64 2x64 2x63 2x65 
2x59 2x65 2x65 2x64 2x66 
2x60 2x66 2x66 2x65 TM3 
2x61 2x67 TM3 2x66 3x21 
2x62 TM3 3x19 TM3 3x22 
2x63 3x18 3x20 3x21 3x23 
TM3 3x19 3x21 3x22 3x24 
3x22 3x20 3x22 3x23 3x25 
3x23 3x21 3x23 3x24 3x26 
3x24 3x22 3x24 3x25 3x27 
3x25 3x23 3x25 3x26 3x28 
3x26 3x24 3x26 3x27 3x29 
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Table A5 (Continued)  
3x27 3x25 3x27 3x28 3x30 
3x28 3x26 3x28 3x29 3x31 
3x29 3x27 3x29 3x30 3x32 
3x30 3x28 3x30 3x31 3x33 
3x31 3x29 3x31 3x32 3x34 
3x32 3x30 3x32 3x33 3x35 
3x33 3x31 3x33 3x34 3x36 
3x34 3x32 3x34 3x35 3x37 
3x35 3x33 3x35 3x36 3x38 
3x36 3x34 3x36 3x37 3x39 
3x37 3x35 3x37 3x38 3x40 
3x38 3x36 3x38 3x39 3x41 
3x39 3x37 3x39 3x40 3x42 
3x40 3x38 3x40 3x41 3x43 
3x41 3x39 3x41 3x42 3x44 
3x42 3x40 3x42 3x43 3x45 
3x43 3x41 3x43 3x44 3x46 
3x44 3x42 3x44 3x45 3x47 
3x45 3x43 3x45 3x46 3x48 
3x46 3x44 3x46 3x47 3x49 
3x47 3x45 3x47 3x48 3x50 
3x48 3x46 3x48 3x49 3x51 
3x49 3x47 3x49 3x50 3x52 
3x50 3x48 3x50 3x51 3x53 
3x51 3x49 3x51 3x52 3x54 
3x52 3x50 3x52 3x53 3x55 
3x53 3x51 3x53 3x54 3x56 
3x54 3x52 3x54 3x55 TM4 
3x55 3x53 3x55 3x56 4x38 
3x56 3x54 3x56 TM4 4x39 
TM4 3x55   4x38 4x40 
4x41 3x56   4x39 4x41 
4x42 TM4 TM4 4x40 4x42 
4x43 4x41 4x38 4x41 4x43 
4x44 4x42 4x39 4x42 4x44 
4x45 4x43 4x40 4x43 4x45 
4x46 4x44 4x41 4x44 4x46 
4x47 4x45 4x42 4x45 4x47 
4x48 4x46 4x43 4x46 4x48 
4x49 4x47 4x44 4x47 4x49 
4x491 4x48 4x45 4x48 4x50 
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Table A5 (Continued)  
4x50 4x49 4x46 4x49 4x51 
4x51 4x491 4x47 4x50 4x52 
4x52 4x50 4x48 4x51 4x53 
4x53 4x51 4x49 4x52 4x54 
4x54 4x52 4x50 4x53 4x55 
4x55 4x53 4x51 4x54 4x56 
4x56 4x54 4x52 4x55 4x57 
4x57 4x55 4x53 4x56 4x58 
4x58 4x56 4x54 4x57 4x59 
4x59 4x57 4x55 4x58 4x60 
4x60 4x58 4x56 4x59 4x61 
4x61 4x59 4x57 4x60 4x62 
4x62 4x60 4x59 4x61 4x63 
4x63 4x61 4x60 4x62 TM5 
4x64 4x62 4x61 4x63 5x36 
4x65 4x63 4x62 4x64 5x37 
4x66 4x64 4x63 TM5 5x38 
4x67 4x65 4x64 5x36 5x39 
4x68 4x66 4x65 5x37 5x40 
TM5 4x67   5x38 5x41 
5x40 4x68   5x39 5x411 
5x41 TM5 TM5 5x40 5x42 
5x42 5x37 5x33 5x41 5x43 
5x421 5x38 5x34 5x42 5x44 
5x43 5x39 5x35 5x43 5x45 
5x44 5x40 5x36 5x44 5x46 
5x45 5x41 5x37 5x45 5x461 
5x46 5x42 5x38 5x46 5x47 
5x47 5x421 5x39 5x461 5x48 
5x48 5x43 5x40 5x47 5x49 
5x49 5x44 5x41 5x48 5x50 
5x50 5x45 5x42 5x49 5x51 
5x51 5x46 5x43 5x50 5x52 
5x52 5x47 5x44 5x51 5x53 
5x53 5x48 5x45 5x52 5x54 
5x54 5x49 5x46 5x53 5x55 
5x55 5x50 5x461 5x54 5x56 
5x56 5x51 5x47 5x55 5x57 
5x57 5x52 5x48 5x56 5x58 
5x58 5x53 5x49 5x57 5x59 
5x59 5x54 5x50 5x58 5x60 
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Table A5 (Continued) 
5x60 5x55 5x51 5x59 5x61 
5x61 5x56 5x52 5x60 5x62 
5x62 5x57 5x53 5x61 5x63 
5x63 5x58 5x54 5x62 5x64 
5x64 5x59 5x55 5x63 5x65 
5x65 5x60 5x56 5x64 5x66 
5x66 5x61 5x57 5x65 5x67 
5x67 5x62 5x58 5x66 5x68 
5x68 5x63 5x59 5x67 5x69 
5x69 5x64 5x60 5x68 5x70 
TM6 5x65 5x61 5x69 5x71 
6x25 5x66 5x62 5x70 5x72 
6x26 5x67 5x63 5x71 5x73 
6x27 5x68 5x64 5x72 5x74 
6x28 5x69 5x65 5x73 TM6 
6x29 5x70 5x66 5x74 6x21 
6x30 5x71 5x67 5x75 6x22 
6x31 TM6 5x68 5x76 6x23 
6x32 6x28 5x69 TM6 6x24 
6x33 6x29 5x70 6x24 6x25 
6x34 6x30 5x71 6x25 6x26 
6x35 6x31 5x72 6x26 6x27 
6x36 6x32 5x73 6x27 6x28 
6x37 6x33 5x74 6x28 6x29 
6x38 6x34 5x75 6x29 6x30 
6x39 6x35 5x76 6x30 6x31 
6x40 6x36 TM6 6x31 6x32 
6x41 6x37 6x24 6x32 6x33 
6x42 6x38 6x25 6x33 6x34 
6x43 6x39 6x26 6x34 6x35 
6x44 6x40 6x27 6x35 6x36 
6x45 6x41 6x28 6x36 6x37 
6x46 6x42 6x29 6x37 6x38 
6x47 6x43 6x30 6x38 6x39 
6x48 6x44 6x31 6x39 6x40 
6x49 6x45 6x32 6x40 6x41 
6x50 6x46 6x33 6x41 6x42 
6x51 6x47 6x34 6x42 6x43 
6x52 6x48 6x35 6x43 6x44 
6x53 6x49 6x36 6x44 6x45 
TM7 6x50 6x37 6x45 6x46 
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Table A5 (Continued) 
7x28 6x51 6x38 6x46 6x47 
7x29 6x52 6x39 6x47 6x48 
7x30 6x53 6x40 6x48 6x49 
7x31 TM7 6x41 6x49 6x50 
7x32 7x26 6x42 6x50 6x51 
7x33 7x27 6x43 6x51 6x52 
7x34 7x28 6x44 6x52 6x53 
7x35 7x29 6x45 6x53 6x54 
7x36 7x30 6x46 6x54 6x55 
7x37 7x31 6x47 6x55 6x56 
7x38 7x32 6x48 6x56 6x57 
7x39 7x33 6x49 6x57 6x58 
7x40 7x34 6x50 6x58 6x59 
7x41 7x35 6x51 6x59 6x60 
7x42 7x36 6x52 6x60 6x61 
7x43 7x37 6x53 6x61 TM7 
7x45 7x38 6x54 TM7 7x30 
7x46 7x39 6x55 7x30 7x31 
7x47 7x40 6x56 7x31 7x32 
7x48 7x41 6x57 7x32 7x33 
7x49 7x42 6x58 7x33 7x34 
7x50 7x43 6x59 7x34 7x35 
7x51 7x45 6x60 7x35 7x36 
7x52 7x46 6x61 7x36 7x37 
7x53 7x47 TM7 7x37 7x38 
7x54 7x48 7x30 7x38 7x39 
7x55 7x49 7x31 7x39 7x40 
7x56 7x50 7x32 7x40 7x41 
H8 7x51 7x33 7x41 7x42 
8x47 7x52 7x34 7x42 7x43 
8x48 7x53 7x35 7x43 7x45 
8x49 7x54 7x36 7x45 7x46 
8x50 7x55 7x37 7x46 7x47 
8x51 7x56 7x38 7x47 7x48 
8x52 H8 7x39 7x48 7x49 
8x53 8x47 7x40 7x49 7x50 
8x54 8x48 7x41 7x50 7x51 
8x55 8x49 7x42 7x51 7x52 
8x56 8x50 7x43 7x52 7x53 
8x57 8x51 7x45 7x53 7x54 
8x58 8x52 7x46 7x54 7x55 
138 
 
Table A5 (Continued) 
8x59 8x53 7x47 7x55 7x56 
8x60 8x54 7x48 H8 H8 
8x61 8x55 7x49 8x47 8x47 
8x62 8x56 7x50 8x48 8x48 
8x63 8x57 7x51 8x49 8x49 
8x64 8x58 7x52 8x50 8x50 
8x65 8x59 7x53 8x51 8x51 
8x66 8x60 7x54 8x52 8x52 
8x67 8x61 7x55 8x53 8x53 
8x68 8x62 7x56 8x54 8x54 
8x69 8x63 H8 8x55 8x55 
8x70 8x64 8x47 8x56 8x56 
8x71 8x65 8x48 8x57 8x57 
8x72 8x66 8x49 8x58 8x58 
 8x67 8x50 8x59 8x59 
 8x68 8x51  8x60 
 8x69 8x52  8x61 
 8x70 8x53  8x62 
 8x71 8x54  8x63 
 8x72 8x55  8x64 
  8x56  8x65 
  8x57  8x66 
  8x58  8x67 
    8x68 






GLP-1 Receptor in Complex with a Full Agonist and a Biased Agonist Probed by 
Molecular Dynamics Simulations for the Development of more Specific Drugs on 
Type 2 Diabetes 
 
 
Figure B1. Protein secondary structures timeline for the full agonist system. The top plot 
summarizes the SSE composition for each trajectory frame over the course of the 











Figure B3. Protein ligand contacts for the full unbiased agonist obtained from the SID 
analysis. Types of interaction (H-bond, hydrophobic, ionic, water bridges) are shown for 





Figure B4.  Protein-ligand contacts for the full agonist over time. The top panel shows 
the total number of specific contacts the protein makes with the ligand over time. The 
bottom panel shows which residues interact with the ligand in each trajectory frame. 




Figure B5.  Ligand torsions profile for the full unbiased agonist. Summarizes the 





Figure B6. Ligand properties of the full agonist. Ligand RMSD: Root mean square 
deviation of a ligand with respect to the reference conformation (typically the first frame 
is used as the reference and it is regarded as time t=0). Radius of Gyration (rGyr): 
Measures the 'extendedness' of a ligand, and is equivalent to its principal moment of 
inertia. Intramolecular Hydrogen Bonds (intraHB): Number of internal hydrogen 
bonds (HB) within a ligand molecule. Molecular Surface Area (MolSA): Molecular 
surface calculation with 1.4 Å probe radius. This value is equivalent to a van der Waals 
surface area. Solvent Accessible Surface Area (SASA): Surface area of a molecule 
accessible by a water molecule. Polar Surface Area (PSA): Solvent accessible surface 





Figure B7. Protein secondary structures timeline for the biased agonists system. The top 
plot summarizes the SSE composition for each trajectory frame over the course of the 





Figure B8. Protein secondary structures timeline for the APO form system. The top plot 
summarizes the SSE composition for each trajectory frame over the course of the 








Figure B9. Comparison between our full unbiased agonist system and the solved 




Full Agonist System PDB ID: 5G53 Superimposition  
 
  
Figure B10. Comparison between our full unbiased agonist complex and the solved 








Figure B11. Comparison between our full unbiased agonist complex and the solved 








Figure B12. Comparison between our full unbiased agonist complex and the solved 









Figure B13. Comparison between our biased agonist complex and the solved structure for 
G protein docked Adrenergic receptor obtained from PDB. The C-terminal helix is 




Biased Agonist System PDB ID: 5G53 Superimposition  
 
  
Figure B14. Comparison between our biased agonist complex and the solved structure for 
G protein docked Adenosine A2A receptor obtained from PDB. The C-terminal helix is 









Figure B15. Comparison between our biased agonist complex and the solved structure for 
G protein docked Calcitonin receptor obtained from the PDB. The C-terminal helix is 




Biased Agonist System PDB ID: 5VAI Superimposition  
  
 
Figure B16. Comparison between our biased agonist complex and the solved structure of 
G protein docked Calcitonin receptor obtained from PDB. The C-terminal helix is circled 




Full Agonist APO Form Superimposed 
   
Figure S17. Comparison of conformational change between full unbiased agonist and 




Biased Agonist APO Form Superimposed 
 
  
Figure B18. Comparison of conformational change between biased agonist and APO 





Figure B19. Pairwise comparison of all ECDs after MD simulations to observe 





Figure B20. Comparison of all C-terminal helices to observe conformational differences. 
Red = full unbiased agonist, Blue = APO, Green = biased agonist.  
 
